GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rainmed Medical Ltd (HKSE:02297) » Definitions » EBITDA Margin %

Rainmed Medical (HKSE:02297) EBITDA Margin % : -156.28% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rainmed Medical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rainmed Medical's EBITDA for the six months ended in Jun. 2024 was HK$-45.20 Mil. Rainmed Medical's Revenue for the six months ended in Jun. 2024 was HK$28.93 Mil. Therefore, Rainmed Medical's EBITDA margin for the quarter that ended in Jun. 2024 was -156.28%.


Rainmed Medical EBITDA Margin % Historical Data

The historical data trend for Rainmed Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rainmed Medical EBITDA Margin % Chart

Rainmed Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
-2,430.99 -768.44 -1,595.60 -127.76 -259.90

Rainmed Medical Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only -401.36 -83.55 -288.01 -156.28 -525.34

Competitive Comparison of Rainmed Medical's EBITDA Margin %

For the Medical Devices subindustry, Rainmed Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rainmed Medical's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rainmed Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Rainmed Medical's EBITDA Margin % falls into.


;
;

Rainmed Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Rainmed Medical's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-102.314/80.085
=-127.76 %

Rainmed Medical's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-45.203/28.925
=-156.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rainmed Medical  (HKSE:02297) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Rainmed Medical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Rainmed Medical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rainmed Medical Business Description

Traded in Other Exchanges
N/A
Address
No. 99, Jinji Lake Avenue, Building 31, Northeast District, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
Executives
Huo Yunfei 2101 Beneficial owner
Huo Yunlong
Zhou Bin
Zhong Guo Ping An Bao Xian Ji Tuan Gu Fen You Xian Gong Si
Xi Zang Jing Jia Qi Ye Guan Li You Xian Ze Ren Gong Si
Shang Hai Jing Lin Gu Quan Tou Zi Guan Li You Xian Gong Si
Shang Hai Jing Wu Tou Zi Zhong Xin You Xian He Huo
Shang Hai Jing Mai Run Qi Ye Guan Li Zhong Xin You Xian He Huo
Gong Qing Cheng Jing Cheng Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Gong Qing Cheng Jing Lin Jing Jia Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Jing Lin Zi Ben Guan Li You Xian Gong Si
Shen Zhen Jing Lin Jing Ying Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Shen Zhen Jing Hui Gu Quan Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Shang Hai Tong Xiang Hao Qian Qi Ye Guan Li He Huo Qi Ye You Xian He Huo
Xi Zang Jing Ning Qi Ye Guan Li You Xian Ze Ren Gong Si

Rainmed Medical Headlines

No Headlines